APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Site Enhances New Modality CRDMO Platform Capacity for Customers
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
As per partnership, Carbanio will arrange raw materials and other custom chemicals for Proexp Pharma Pvt. Ltd. through an uninterrupted digital process of the company
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
Subscribe To Our Newsletter & Stay Updated
